Skip to Content

Nevirapine

Class: HIV Nonnucleoside Reverse Transcriptase Inhibitors
VA Class: AM800
Chemical Name: 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b: 2′,3′-e)[1,4]diazepin-6-one
Molecular Formula: C15H14N4O
CAS Number: 129618-40-2
Brands: Viramune

Medically reviewed on Aug 13, 2018

Warning

    Hepatotoxicity
  • Severe, life-threatening (and in some cases fatal) hepatotoxicity reported, particularly during first 18 weeks of therapy.1 234 In some cases, patients presented with nonspecific prodromal signs or symptoms of hepatitis and progressed to hepatic failure; these events often associated with rash.1 234 Patients with higher CD4+ T-cell counts at initiation of therapy and women are at increased risk.1 234 Women with CD4+ T-cell counts >250 cells/mm3 (including pregnant women receiving nevirapine with other antiretrovirals for treatment of HIV-1 infection) are at greatest risk, but hepatotoxicity can occur in both genders, all CD4+ T-cell counts, and at any time during treatment. 1 234 Patients with signs or symptoms of hepatitis or with increased serum aminotransferase (transaminase) concentrations in conjunction with rash or other systemic symptoms must discontinue nevirapine and immediately seek medical evaluation.1 234

  • Contraindicated for postexposure prophylaxis of HIV following occupational or nonoccupational exposures;1 234 hepatic failure reported in patients without HIV infection receiving nevirapine for postexposure prophylaxis.1 234

    Skin Reactions
  • Severe, life-threatening skin reaction, including fatal cases, reported.1 234 Reactions include Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction.1 234 Patients with signs or symptoms of severe skin reactions or hypersensitivity must discontinue nevirapine and immediately seek medical evaluation.1 234 Immediately measure serum transaminase concentrations if rash occurs during first 18 weeks of nevirapine therapy.1 234

  • Must be initiated using a lead-in 14-day period of low dosage of conventional (immediate-release) nevirapine (200 mg once daily in adults) since this decreases the incidence of rash.1 234

    Monitoring
  • Must monitor patients intensively during first 18 weeks of therapy to detect potential life-threatening hepatotoxicity or skin reactions.1 234 Extra vigilance warranted during first 6 weeks, the period of greatest risk.1 234

  • Do not restart nevirapine following clinical hepatitis, elevated transaminase concentrations combined with rash or other systemic symptoms, or following severe rash or hypersensitivity reactions.1 234

Introduction

See also: Atripla

Antiretroviral; HIV nonnucleoside reverse transcriptase inhibitor (NNRTI).1 21 200 234

Uses for Nevirapine

Treatment of HIV Infection

Treatment of HIV-1 infection in adults, adolescents, and pediatric patients;1 234 usually used in conjunction with 2 HIV nucleoside reverse transcriptase inhibitors (NRTIs).1 234

Because of increased risk of potentially life-threatening hepatotoxicity, do not initiate in females (including postpubertal girls and adolescents) with pretreatment CD4+ T-cell counts >250/mm3 or in males (including adolescent boys) with CD4+ T-cell counts >400/mm3 unless potential benefits clearly outweigh risks.1 96 200 201 234 (See Hepatic Effects under Cautions.)

For initial treatment in antiretroviral-naive adults or adolescents, experts state nevirapine not recommended since it is associated with serious and potentially fatal toxicity (e.g., hepatic events and severe rash, including Stevens-Johnson syndrome and toxic epidermal necrolysis) and did not meet noninferiority criteria when compared to efavirenz.200

For initial treatment in antiretroviral-naive pediatric patients, experts state that nevirapine and 2 NRTIs is an alternative (not preferred) regimen in those >14 days and <3 years of age.201

Experts state that nevirapine and 2 NRTIs is the regimen of choice for initial treatment in neonates <14 days of age when HIV infection confirmed.201 Consultation with an expert in pediatric HIV infection recommended; unclear whether initiation of antiretroviral treatment within first 14 days of life improves outcome compared with initiation at >14 days of age.201 If used, consider changing to fixed-combination lopinavir and ritonavir (lopinavir/ritonavir) and 2 NRTIs when infant is 14 days of age with postmenstrual age at least 42 weeks (i.e., time elapsed since first day of mother’s last menstrual period to birth plus time elapsed after birth).201

Prevention of Perinatal HIV Transmission

Prophylaxis in neonates born to HIV-infected women for prevention of perinatal HIV transmission;202 used in conjunction with zidovudine.202

Empiric HIV therapy in neonates born to HIV-infected women for prevention of perinatal HIV transmission;202 used in 3-drug empiric regimen (zidovudine, lamivudine, and nevirapine) in neonates at highest risk of HIV acquisition.202

Pregnant HIV-infected women: Multiple-drug antiretroviral regimens are standard of care in the US for treatment of HIV infection in pregnant women and for prevention of perinatal HIV transmission.202 In addition, to further decrease risk of perinatal HIV transmission, experts recommend that all pregnant HIV-infected women with plasma HIV-1 RNA levels >1000 copies/mL (or unknown HIV-1 RNA levels) near delivery receive an intrapartum IV zidovudine prophylaxis regimen initiated at the onset of labor (or 3 hours before scheduled cesarean delivery) and continued until delivery (unless contraindicated).

HIV-exposed neonates: Experts recommend that all neonates born to HIV-infected women (HIV-exposed neonates) receive an antiretroviral regimen (either prophylaxis or empiric HIV therapy) initiated as soon as possible after birth (preferably within 6–12 hours) and continued through 4–6 weeks of age.202 Select antiretroviral prophylaxis regimen or empiric HIV therapy regimen based on likelihood of perinatal HIV transmission.202 HIV-exposed neonates at low risk of perinatal HIV acquisition (i.e., infants born to women who were receiving a recommended multiple-drug antiretroviral regimen during pregnancy with sustained viral suppression near delivery and no concerns related to maternal adherence to the treatment regimen) may receive a 4-week zidovudine prophylaxis regimen used alone.202 HIV-exposed neonates at higher risk of HIV acquisition (e.g., those born to HIV-infected women who did not receive antepartum or intrapartum antiretrovirals, received only intrapartum antiretrovirals, or received antepartum and intrapartum antiretrovirals with suboptimal viral suppression near delivery) should receive a 2-drug prophylaxis regimen (6-week zidovudine prophylaxis and 3-dose nevirapine prophylaxis).202 Alternatively, those at highest risk can receive a 3-drug empiric HIV therapy regimen (zidovudine, lamivudine, and nevirapine).202

Maternal and neonatal regimens recommended for prevention of perinatal HIV transmission in the US may differ from those used in other countries.202

Consult National Perinatal HIV Hotline at 888-448-8765 for information regarding antiretroviral treatment of pregnant HIV-infected women and their infants and prevention of perinatal HIV transmission.202

Nevirapine Dosage and Administration

Administration

Oral Administration

Administer orally with or without food.1 234

Conventional (immediate-release) tablets and oral suspension: Use in adults, adolescents, and pediatric patients ≥15 days of age.1

Extended-release tablets: Use in adults, adolescents, and pediatric patients ≥6 years of age.234

Extended-release Tablets

Extended-release tablets: Swallow whole;234 do not chew, crush, or divide.234

When considering use in a child ≥6 years of age, assess child for ability to swallow tablets.234

Oral Suspension

Shake suspension gently prior to each dose.1

Administer using calibrated dosing syringe (especially for volumes <5 mL).1 Alternatively, administer using dosing cup;1 rinse cup with water and administer the rinse to the patient.1

Dosage

Available as nevirapine (immediate-release tablets, extended-release tablets) and nevirapine hemihydrate (oral suspension);1 234 dosage expressed in terms of nevirapine.1 234

Initiate therapy using a low dosage of immediate-release nevirapine for first 14 days since this appears to reduce frequency of rash.1 48 49 67 234 Do not use extended-release tablets during initial 14 days of nevirapine therapy.234

If mild to moderate rash without constitutional symptoms occurs during initial 14-day period of low dosage of immediate-release nevirapine, do not increase dosage until rash resolves.1 234 Do not continue initial low dosage beyond 28 days;1 234 if rash does not resolve by day 28, discontinue nevirapine and select alternative therapy.1 234

If nevirapine therapy has been interrupted for >7 days for any reason and is not contraindicated, restart using the recommended low initial dosage of immediate-release nevirapine for first 14 days.1 234

Pediatric Patients

Dosage usually based on body surface area (BSA) calculated using Mosteller formula.1 201 234 Investigational dosage based on weight has been recommended in certain neonates.201 202

Treatment of HIV Infection
Oral

Neonates <14 days of age: If gestational age 34 to <37 weeks, experts recommend 4 mg/kg twice daily from birth to 1 week of age, then 6 mg/kg twice daily beginning at 1 week of age.202 If gestational age ≥37 weeks, experts recommend 6 mg/kg twice daily.202

Neonates, infants, and children ≥15 days of age (oral suspension or immediate-release tablets): Manufacturer recommends 150 mg/m2 once daily for first 14 days of therapy (lead-in period of low dosage), followed by 150 mg/m2 twice daily.1

Children 6 to <18 years of age (extended-release nevirapine): Manufacturer recommends 200 mg once daily if BSA 0.58–0.83 m2, 300 mg once daily if BSA 0.84–1.16 m2, or 400 mg once daily if BSA ≥1.17 m2.234 If not already receiving nevirapine, use oral suspension or immediate-release tablets for lead-in period of low dosage (150 mg/m2 once daily [up to 200 mg daily]) for first 14 days, then switch to extended-release tablets.234

Experts suggest that infants and children 1 month to <8 years of age require higher dosage than those ≥8 years of age.201 When immediate-release nevirapine used, these experts recommend 200 mg/m2 once daily for 14 days (lead-in period of low dosage) followed by 200 mg/m2 twice daily (up to 200 mg twice daily) in those 1 month to <8 years of age and 120–150 mg/m2 once daily for 14 days (lead-in period of low dosage) followed by 120–150 mg/m2 twice daily (up to 200 mg twice daily) in those ≥8 years of age.201 Some experts suggest lead-in period of low dosage not needed in pediatric patients ≤2 years of age.201

Adolescents: Experts state usual adult dosage can be used.201 (See Adults under Dosage and Administration.)

Prevention of Perinatal HIV Transmission
Prophylaxis in Neonates Born to HIV-infected Women
Oral

Neonates at higher risk of HIV acquisition: 3 nevirapine doses (nevirapine oral suspension) during first week of life initiated as soon as possible after delivery in addition to usual 6-week neonatal zidovudine prophylaxis regimen.202

Give first nevirapine dose within 48 hours of birth, second dose 48 hours after first dose, and third dose 96 hours after second dose.202

Birth weight 1.5–2 kg: Experts recommend 8 mg of nevirapine for each of the 3 doses.202

Birth weight >2 kg: Experts recommend 12 mg of nevirapine for each of the 3 doses.202

Empiric HIV Therapy in Neonates Born to HIV-infected Women
Oral

Recommended empiric HIV therapy regimen consists of zidovudine, lamivudine, and nevirapine initiated as soon as possible after birth (within 6–12 hours);202 used in HIV-exposed neonates considered at highest risk of HIV acquisition.202 (See Prevention of Perinatal HIV Transmission under Uses.)

Gestational age 34 to <37 weeks: Experts recommend 4 mg/kg of nevirapine twice daily from birth to 1 week of age, then 6 mg/kg twice daily beginning at 1 week of age.202

Gestational age ≥37 weeks: Experts recommend 6 mg/kg of nevirapine twice daily.202

Optimal duration of empiric HIV therapy in HIV-exposed neonates unknown.202 Many experts recommend that 3-drug empiric regimen be continued for 6 weeks;202 others discontinue nevirapine and/or lamivudine if results of neonate's HIV nucleic acid amplification test (NAAT) are negative, but recommend continuing zidovudine for 6 weeks.202

Consult National Perinatal HIV Hotline at 888-448-8765 for information regarding selection of antiretrovirals, including dosage considerations, for prevention of perinatal HIV transmission.202

Adults

Treatment of HIV Infection
Oral

Immediate-release tablets: 200 mg once daily for first 14 days (lead-in period of low dosage), followed by 200 mg twice daily.1 200

Extended-release tablets: 400 mg once daily, initiated after immediate-release nevirapine.234 In those not currently receiving nevirapine, use lead-in period of low dosage of immediate-release tablets (200 mg once daily for 14 days) then switch to extended-release tablets 400 mg once daily.234 In those already receiving twice-daily regimen of usual dosage of immediate-release nevirapine, switch to extended-release tablets 400 mg once daily (without 14-day lead-in period).234

Prescribing Limits

Pediatric Patients

Treatment of HIV Infection
Oral

Children ≥15 days of age (oral suspension or immediate-release tablets): Dosage based on BSA (maximum 400 mg daily).1

Children 6 to <18 years of age (extended-release nevirapine): Dosage based on BSA (maximum 400 mg daily).234

Special Populations

Hepatic Impairment

Treatment of HIV Infection
Oral

Immediate-release nevirapine: Data insufficient to make dosage recommendation in patients with mild hepatic impairment (Child-Pugh class A);1 some experts state dosage adjustments not necessary.200 Contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B or C).1

Extended-release tablets: Not studied in patients with hepatic impairment.234 Contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B or C).234

Renal Impairment

Treatment of HIV Infection
Oral

Immediate-release nevirapine: Dosage adjustments not needed in patients with Clcr ≥20 mL/minute not undergoing dialysis.1 Administer additional 200-mg dose of immediate-release nevirapine after each dialysis treatment.1

Extended-release tablets: Not studied in patients with renal impairment.234

Geriatric Patients

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1 234

Cautions for Nevirapine

Contraindications

  • Moderate or severe hepatic impairment (Child-Pugh class B or C).1 234

  • Do not use for postexposure prophylaxis following occupational exposure to HIV (PEP) or for postexposure prophylaxis following nonoccupational exposure to HIV (nPEP).1 198 199 234 (See Hepatic Effects under Cautions.)

Warnings/Precautions

Sensitivity Reactions

Dermatologic and Sensitivity Reactions

Severe, life-threatening skin reactions (including some fatalities) reported.1 234 Anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous eruptions, ulcerative stomatitis, urticaria, drug reaction with eosinophilia and systemic symptoms (DRESS), and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction (including hepatic failure) reported.1 234

Patients with signs or symptoms of severe skin or hypersensitivity reactions (severe rash or rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, and/or hepatitis, eosinophilia, granulocytopenia, lymphadenopathy, and renal dysfunction) must permanently discontinue nevirapine and seek immediate medical evaluation.1 234

Must be initiated using low dosage of immediate-release nevirapine for first 14 days (200 mg once daily in adults or 150 mg/m2 once daily in pediatric patients); this lead-in period of low dosage reduces frequency of rash.1 234 If mild to moderate rash without constitutional symptoms occurs during initial 14 days, dosage should not be increased until rash resolves.1 234 Do not continue initial low dosage beyond 28 days; discontinue nevirapine and select alternative therapy.1 234

Monitor closely if isolated rash of any severity occurs.1 234

Risk factors for severe cutaneous reactions include failure to follow recommended initial low dosage during first 14 days and delay in discontinuing nevirapine after onset of initial symptoms.1 234

Women appear to be at higher risk of developing rash than men.1 234

Prednisone not recommended for prevention of nevirapine-associated rash.1 234 (See Specific Drugs under Interactions.)

Do not restart nevirapine following hypersensitivity reaction, severe rash, or rash in conjunction with increased serum transaminase concentrations or other systemic symptoms.1 234

Patient Monitoring

Serious adverse effects include hepatitis, hepatic failure, Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions reported.1

Intensive monitoring required during first 18 weeks of therapy to detect potentially life-threatening hepatic events and skin reactions; extra vigilance warranted during first 6 weeks (period of greatest risk).1 234 Optimum frequency of monitoring during this period not established;1 234 some experts recommend clinical and laboratory monitoring more often than once monthly and liver function tests at baseline, prior to dosage escalation, and 2 weeks after dosage escalation.1 234

Continue frequent clinical and laboratory monitoring after initial 18-week period and throughout nevirapine therapy.1 234

Hepatic Effects

Severe, life-threatening (and in some cases fatal) hepatotoxicity, including fulminant and cholestatic hepatitis (e.g., transaminase elevations with or without hyperbilirubinemia, prolonged partial thromboplastin time, or eosinophilia), hepatic necrosis, and hepatic failure, reported.1 234 Hepatic events can occur at any time during therapy.1 234 Risk of hepatic events (regardless of severity) greatest during the first 6 weeks of therapy; substantial risk continues through 18 weeks of therapy.1 234

Some patients present with nonspecific prodromal signs and symptoms of fatigue, malaise, anorexia, nausea, jaundice, liver tenderness, and/or hepatomegaly, with or without initially abnormal serum transaminase concentrations.1 Rash observed in 50% of those with symptomatic hepatic adverse events.1 234 Fever and flu-like symptoms accompany some of these hepatic events.1 234 Some events, particularly those with rash or other symptoms, have progressed to hepatic failure with serum transaminase elevation, with or without hyperbilirubinemia, hepatic encephalopathy, prolonged partial thromboplastin time, and/or eosinophilia.1 86 234

Patients with higher CD4 counts and women are at increased risk of hepatic events.1 234 Women with CD4 counts >250 cells/mm3, including pregnant women receiving long-term treatment for HIV infection, are at considerably higher risk of these events.1 234 Increased liver enzymes and/or HBV or HCV infection associated with increased risk.1 234

Serious hepatotoxicity reported in individuals not infected with HIV who received nevirapine as part of a multiple-drug regimen for postexposure prophylaxis following occupational or nonoccupational exposure to HIV.1 86 87 Do not use in HIV postexposure prophylaxis regimens following occupational or nonoccupational exposure to the virus.1 199 234

Intensive clinical and laboratory monitoring essential.1 234 (See Patient Monitoring under Cautions.)

Consider possibility of hepatotoxicity if there are signs or symptoms of hepatitis (e.g., fatigue, malaise, anorexia, nausea, jaundice, bilirubinuria, acholic stools, liver tenderness or hepatomegaly), even if liver function tests are initially normal or alternative diagnosis is possible.1 234

Hepatic injury has progressed despite discontinuation of nevirapine in some patients.1 234

Patients with signs and symptoms of hepatitis must seek immediate medical attention, have liver function tests performed (serum transaminase concentrations), and be advised to discontinue nevirapine as soon as possible.1 86 234 If nevirapine is discontinued because of hepatitis or increased serum transaminase concentrations associated with rash or other systemic symptoms, it should be permanently discontinued and not reinitiated.1 86 234

Interactions

Concomitant use with certain drugs not recommended (e.g., St. John’s wort).1 234 (See Specific Drugs under Interactions.)

Adipogenic Effects

Possible redistribution or accumulation of body fat, including central obesity, dorsocervical fat enlargement (“buffalo hump”), peripheral wasting, breast enlargement, and general cushingoid appearance.1 234 Mechanisms and long-term consequences of fat redistribution unknown; causal relationship not established.1 234

Immune Reconstitution Syndrome

During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium complex [MAC], M. tuberculosis, cytomegalovirus [CMV], Pneumocystis jirovecii [formerly P. carinii]); this may necessitate further evaluation and treatment.1 101 234

Autoimmune disorders (e.g., Graves' disease, polymyositis, Guillain-Barré syndrome) also reported in the setting of immune reconstitution; however, time to onset is variable and can occur many months after initiation of antiretroviral therapy.1 234

Specific Populations

Pregnancy

Antiretroviral Pregnancy Registry (APR) at 800-258-4263 or [Web].1 202 234

Available data from the APR do not indicate an increased risk for overall major birth defects among infants born to women who received nevirapine during pregnancy compared with US background rate for major birth defects.1 234

Experts states that nevirapine in conjunction with 2 NRTIs not recommended for initial treatment in antiretroviral-naive pregnant women because of greater potential for adverse events, complex lead-in dosage regimen, and low barrier for HIV resistance.202

Severe hepatic events, including fatalities, reported in HIV-infected pregnant women receiving long-term nevirapine therapy as part of multiple-drug antiretroviral treatment.1 234 Because of risk of potentially life-threatening hepatotoxicity, do not initiate nevirapine in pregnant women with pretreatment CD4+ T-cell counts >250/mm3 unless potential benefits clearly outweigh risks.1 96 200 If initiated in such women, caution recommended.202 (See Hepatic Effects under Cautions.)

May be continued if tolerated in women who become pregnant, regardless of CD4+ T-cell count.202

Fertility

Evidence of impaired fertility in female rats at exposure level approximately equivalent to that provided by usually recommended human dosage.1 234 Human data insufficient to determine risk of infertility in patients receiving nevirapine.1 234

Advise females with reproductive potential that, based on results from fertility studies in rats, nevirapine may impair fertility and it is not known whether effects on fertility are reversible.1 234

Lactation

Distributed into milk.1 58 65 234

Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.1 202 234

Pediatric Use

Immediate-release tablets and oral suspension: Safety and pharmacokinetics evaluated in children 15 days to <3 months of age.1 Safety, pharmacokinetics, and efficacy evaluated in children 3 months to 18 years of age.1

Extended-release nevirapine: Can be used in children ≥6 years of age based on pharmacokinetic, safety, and antiretroviral activity data in pediatric patients 3 to <18 years of age and efficacy data from adults.234 Not recommend in those 3 to <6 years of age because of insufficient pharmacokinetic data in this age group;234 not recommended in those <3 years of age because of inability to swallow tablets.234

Immediate-release nevirapine recommended by some experts for initial treatment of confirmed HIV infection in certain neonates <14 days of age (see Treatment of HIV Infection under Uses).201 Also recommended for prophylaxis or empiric HIV therapy for perinatal HIV transmission in certain neonates <14 days of age (see Prevention of Perinatal HIV Transmission under Uses).202

Adverse effects reported in children generally similar to those reported in adults; granulocytopenia reported more frequently in children than adults.1 Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome reported rarely.1 Allergic reactions, including anaphylaxis, also reported.1

Geriatric Use

Insufficient experience in those ≥65 years of age to determine whether they respond differently than younger adults.1 234

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.1 234

Hepatic Impairment

Carefully monitor those with hepatic impairment (e.g., those with hepatic fibrosis or cirrhosis) for toxicity.1

Contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh class B or C).1 234

Renal Impairment

Modification of usual dosage of immediate-release nevirapine dosage forms not necessary in patients with Clcr ≥20 mL/minute not requiring dialysis;1 additional dose of immediate-release nevirapine necessary following dialysis.1 Pharmacokinetics not evaluated in those with Clcr <20 mL/minute.1 234 (See Renal Impairment under Dosage and Administration.)

Extended-release tablets not studied in patients with renal impairment.234

Common Adverse Effects

Rash, nausea, headache, fatigue, abnormal liver function test results.1 234 Adverse effects reported with extended-release tablets similar to those reported with immediate-release tablets.234

Interactions for Nevirapine

Metabolized by CYP3A and CYP2B6.1 234

Inhibits CYP3A and CYP2B6.1 234

Induces CYP3A and CYP2B6.1 234

The following drug interactions are based on studies using nevirapine immediate-release tablets and are expected to also apply to extended-release tablets.1 234

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interactions likely with drugs that are inhibitors, inducers, or substrates of CYP3A or 2B6 with possible alteration in metabolism of nevirapine and/or other drug.1 47 234

Nevirapine does not appear to affect plasma concentrations of drugs that are substrates of other CYP isoenzymes (e.g., 1A2, 2D6, 2A6, 2E1, 2C9, 2C19).1 234

Specific Drugs

Drug

Interaction

Comments

Abacavir

No in vitro evidence of antagonistic antiretroviral effects1 234

Antacids (Maalox)

No effect on nevirapine absorption1

Immediate-release nevirapine may be administered with antacids1

Antiarrhythmic agents (amiodarone, disopyramide, lidocaine)

Possible decreased antiarrhythmic agent concentrations1 234

Appropriate dosages for concomitant use not established1 234

Anticoagulants

Apixaban, rivaroxaban: Possible decreased anticoagulant concentrations200

Betrixaban, dabigatran, edoxaban: Altered anticoagulant concentrations not expected200

Warfarin: Possible altered warfarin concentrations and increased or decreased anticoagulant effects1 200 234

Apixaban, rivaroxaban: Consider alternative therapy200

Betrixaban, dabigatran, edoxaban: Dosage adjustments not needed200

Warfarin: Closely monitor INR; adjust warfarin dosage accordingly1 200 234

Anticonvulsants (carbamazepine, clonazepam, eslicarbazepine, ethosuximide, phenobarbital, phenytoin)

Carbamazepine, clonazepam, phenobarbital, phenytoin: Possible decreased anticonvulsant concentrations1 200 234

Eslicarbazepine: Possible decreased nevirapine concentrations200

Ethosuximide: Possible decreased ethosuximide and nevirapine concentrations1 234

Carbamazepine, clonazepam, phenobarbital, phenytoin: Use concomitantly with caution;1 234 monitor anticonvulsant and nevirapine concentrations and antiretroviral response;1 200 234 alternatively, consider different anticonvulsant200

Eslicarbazepine: Monitor antiretroviral response and consider monitoring nevirapine concentrations;200 alternatively, consider different anticonvulsant or different antiretroviral200

Ethosuximide: Use concomitantly with caution;1 234 monitor ethosuximide concentrations and antiretroviral response1 234

Antidiabetic agents

Canagliflozin, dapagliflozin, empagliflozin, sitagliptin: Altered antidiabetic agent concentrations not expected200

Linagliptin, saxagliptin: Possible decreased antidiabetic agent concentrations200

Canagliflozin, dapagliflozin, empagliflozin, sitagliptin: Dosage adjustments not needed200

Linagliptin, saxagliptin: Monitor glycemic control200

Antifungals, azoles

Fluconazole: Increased nevirapine concentrations;1 234 no effect on fluconazole concentrations;1 234 possible increased risk of hepatotoxicity200

Isavuconazonium (prodrug of isavuconazole): Possible decreased isavuconazole concentrations200

Itraconazole: Possible decreased itraconazole concentrations and reduced antifungal efficacy1 234

Ketoconazole: Possible decreased ketoconazole concentrations and reduced antifungal efficacy1 200 234

Posaconazole: Possible increased nevirapine concentrations200

Voriconazole: Possible decreased voriconazole concentrations and increased nevirapine concentrations200

Fluconazole: Use concomitantly with caution;1 234 closely monitor for nevirapine adverse effects;1 200 234 consider alternative antiretroviral200

Isavuconazonium: Antifungal dosage adjustment may be needed;200 consider monitoring isavuconazole concentrations and antifungal response200

Itraconazole: Concomitant use not recommended;1 234 if used, monitor itraconazole concentrations and adjust itraconazole dosage accordingly200

Ketoconazole: Concomitant use not recommended1 200 234

Posaconazole: Monitor for nevirapine-associated adverse effects200

Voriconazole: Monitor frequently for adverse effects or toxicity and response to voriconazole; monitor voriconazole plasma concentrations200

Antimalarial agents

Fixed combination of artemether and lumefantrine (artemether/lumefantrine): Decreased AUC of artemether and active metabolite of artemether (dihydroartemisinin);200 possible altered (increased or decreased) AUC of lumefantrine200

Artemether/lumefantrine: Clinical importance unknown; monitor for antimalarial efficacy and lumefantrine toxicity200

Antimycobacterials (rifabutin, rifampin, rifapentine)

Bedaquiline: No effect on bedaquiline AUC200

Rifabutin: Increased rifabutin concentrations (high intersubject variability, some patients may experience large increases in rifabutin exposure); decreased nevirapine concentrations1 234

Rifampin: Decreased nevirapine concentrations1 200 234

Rifapentine: Possible decreased nevirapine concentrations200

Bedaquiline: Dosage adjustments not needed 200

Rifabutin: Use concomitantly with caution;1 200 234 dosage adjustment not needed200

Rifampin: Concomitant use not recommended200

Rifapentine: Concomitant use not recommended200

Antiplatelet agents

Clopidogrel, prasugrel: Altered antiplatelet agent concentrations not expected200

Ticagrelor: Decreased ticagrelor concentrations expected200

Clopidogrel, prasugrel: Dosage adjustments not needed200

Ticagrelor: Some experts state consider alternative therapy200

Antipsychotics (lurasidone, olanzapine, pimozide, quetiapine, thioridazine)

Lurasidone, pimozide, quetiapine, thioridazine: Possible decreased antipsychotic concentrations200

Olanzapine: Altered olanzapine concentrations not expected200

Lurasidone, pimozide, quetiapine, thioridazine: Monitor for antipsychotic effects200

Olanzapine: Dosage adjustments not needed200

Atazanavir

Ritonavir-boosted atazanavir: Decreased atazanavir concentrations and AUC; increased nevirapine concentrations and AUC1 200 203 234

Cobicistat-boosted atazanavir: Possible decreased atazanavir and cobicistat concentrations200

Unboosted atazanavir: Possible decreased atazanavir concentrations200

No in vitro evidence of antagonistic antiretroviral effects1 203 234

Ritonavir-boosted, cobicistat-boosted, or unboosted atazanavir: Concomitant use contraindicated203 238

Avanafil

Possible decreased avanafil concentrations200

May need to increase avanafil dosage based on clinical effects200

Benzodiazepines

Alprazolam, diazepam: Possible decreased benzodiazepine concentrations200

Alprazolam, diazepam: Monitor for therapeutic effectiveness of the benzodiazepine200

Buprenorphine

Sublingual or buccal buprenorphine: No clinically important pharmacokinetic interactions200

Buprenorphine implants: Data not available200

Sublingual or buccal buprenorphine: Dosage adjustments not needed200

Buprenorphine implants: If nevirapine initiated, clinical monitoring recommended200

Bupropion

Decreased bupropion AUC200

Titrate bupropion dosage based on clinical response200

Calcium-channel blocking agents (diltiazem, nifedipine, verapamil)

Possible decreased concentrations of the calcium-channel blocking agent1 200 234

Appropriate dosages for concomitant use not established;1 234 if used concomitantly, titrate dosage of calcium-channel blocking agent based on clinical response200

Cisapride

Possible decreased cisapride concentrations1

Appropriate dosages for concomitant use not established1 234

Corticosteroids

Dexamethasone: Possible decreased nevirapine concentrations200

Prednisone: Concomitant use during first 14 days of nevirapine has been associated with increased incidence and severity of rash during first 6 weeks of nevirapine1 234

Dexamethasone: Monitor antiretroviral response;200 consider alternative corticosteroid for long-term therapy200

Prednisone: Concomitant use not recommended1 234

Cyclophosphamide

Possible decreased cyclophosphamide concentrations1 234

Appropriate dosages for concomitant use not established1 234

Daclatasvir

Decreased daclatasvir concentrations178

Use daclatasvir dosage of 90 mg once daily178 200

Darunavir

Ritonavir-boosted darunavir: Increased darunavir concentrations and AUC;1 200 204 234 increased nevirapine concentrations and AUC200 204 234

Cobicistat-boosted darunavir: Decreased darunavir and cobicistat concentrations200

No in vitro evidence of antagonistic antiretroviral effects1 204 234

Ritonavir-boosted darunavir: Dosage adjustment not needed if used concomitantly with nevirapine200 204

Cobicistat-boosted darunavir: Do not use concomitantly200

Dasabuvir, ombitasvir, paritaprevir, and ritonavir

Fixed combination of dasabuvir, ombitasvir, paritaprevir, and ritonavir (dasabuvir/ombitasvir/paritaprevir/ritonavir) or fixed combination of ombitasvir, paritaprevir, and ritonavir (ombitasvir/paritaprevir/ritonavir) copackaged with dasabuvir (ombitasvir/paritaprevir/ritonavir with dasabuvir): Possible decreased HCV antiviral concentrations200

Dasabuvir/ombitasvir/paritaprevir/ritonavir (fixed combination) or ombitasvir/paritaprevir/ritonavir with dasabuvir (copackaged): Do not use concomitantly200

Delavirdine

Possible altered delavirdine concentrations1 234

Do not use concomitantly1 200 234

Didanosine

No effect on nevirapine or didanosine pharmacokinetics1 234

No in vitro evidence of antagonistic antiretroviral effects1 234

Dolutegravir

Possible decreased dolutegravir concentrations200 236

No in vitro evidence of antagonistic antiretroviral effects236

Do not use concomitantly;200 236 data insufficient to make dosage recommendations236

Dutasteride

Possible decreased dutasteride concentrations200

Monitor and adjust dutasteride dosage if needed200

Efavirenz

Decreased efavirenz concentrations and AUC;1 234 increased incidence of adverse effects and no improvement in efficacy1 234

Do not use concomitantly;1 200 234 appropriate dosages for concomitant use with respect to safety and efficacy not established1 234

Elbasvir and grazoprevir

Fixed combination of elbasvir and grazoprevir (elbasvir/grazoprevir): Decreased elbasvir and grazoprevir concentrations expected200

Elbasvir/grazoprevir: Do not use concomitantly200

Elvitegravir and cobicistat

Fixed combination of elvitegravir, cobicistat, emtricitabine, and either tenofovir alafenamide (EVG/c/FTC/TAF) or tenofovir disoproxil fumarate (EVG/FTC/TDF): Possible altered (increased or decreased) concentrations of elvitegravir, cobicistat, and/or nevirapine200

EVG/c/FTC/TAF, EVG/c/FTC/TDF: Do not use concomitantly with nevirapine200

Emtricitabine

No in vitro evidence of antagonistic antiretroviral effects1 234

Ergot alkaloids (dihydroergotamine, ergotamine, methylergonovine)

Possible decreased concentrations of the ergot alkaloid;1 202 possible inadequate treatment effects202

Ergotamine: Appropriate dosages for concomitant use not established1 234

If methylergonovine used to treat postpartum hemorrhage in a woman receiving nevirapine, additional uterotonic agents may be needed202

Estrogens and progestins

Drospirenone, medroxyprogesterone, progesterone: Possible decreased concentrations of the progestin200

Estradiol, conjugated estrogens: Possible decreased estrogen concentrations200

Implants containing etonogestrel or levonorgestrel: No effect on progestin concentrations200

Oral contraceptives containing ethinyl estradiol and norethindrone: Decreased ethinyl estradiol and norethindrone AUC;1 234 does not appear to affect pregnancy rates in HIV-infected women1 200 234

Drospirenone, medroxyprogesterone, progesterone: Monitor and use lowest effective progestin dosage to achieve clinical effects200

Estradiol, conjugated estrogens: Monitor and use lowest effective estrogen dosage to achieve clinical effects200

Implants containing etonogestrel or levonorgestrel: Dosage adjustments not needed200

Oral contraceptives containing ethinyl estradiol and norethindrone: Dosage adjustments not needed1 200 234

Etravirine

Possible altered etravirine concentrations1 234

Do not use concomitantly1 200 234

Fentanyl

Possible decreased fentanyl concentrations1 234

Appropriate dosages for concomitant use not established1 234

Finasteride

Possible decreased finasteride concentrations200

Monitor and adjust finasteride dosage if needed200

Fosamprenavir

Fosamprenavir (without low-dose ritonavir): Decreased amprenavir (active metabolite of fosamprenavir) AUC and increased nevirapine AUC1 205 234

Ritonavir-boosted fosamprenavir (twice-daily regimen): Decreased amprenavir AUC and increased nevirapine AUC1 205 234

Ritonavir-boosted fosamprenavir (once-daily regimen): Concomitant use with nevirapine not studied205

No in vitro evidence of antagonistic antiretroviral effects205

Fosamprenavir (without low-dose ritonavir): Concomitant use with nevirapine not recommended1 205 234

Ritonavir-boosted fosamprenavir (twice-daily regimen): Use usual nevirapine dosage with fosamprenavir 700 mg twice daily and ritonavir 100 mg twice daily1 205 234

Glecaprevir and pibrentasvir

Fixed combination of glecaprevir and pibrentasvir (glecaprevir/pibrentasvir): Possible decreased glecaprevir and pibrentasvir concentrations200

Glecaprevir/pibrentasvir: Do not use concomitantly200

Goserelin

Altered goserelin concentrations not expected200

HMG-CoA reductase inhibitors (statins)

Atorvastatin: Possible decreased atorvastatin concentrations200

Lovastatin, simvastatin: Possible decreased concentrations of the statin200

Pitavastatin, rosuvastatin: Altered statin concentrations not expected200

Atorvastatin: Adjust statin dosage based on lipid response and do not exceed maximum recommended statin dosage200

Lovastatin, simvastatin: Adjust statin dosage based on lipid response and do not exceed maximum recommended statin dosage;200 avoid lovastatin and simvastatin if nevirapine used in a regimen that includes a ritonavir-boosted PI200

Pitavastatin, rosuvastatin: Dosage adjustments not needed200

Immunosuppressive agents

Cyclosporine, everolimus, sirolimus, tacrolimus: Possible decreased concentrations of immunosuppressive agent1 200 234

Cyclosporine, everolimus, sirolimus, tacrolimus: Appropriate dosages for concomitant use not established;1 234 therapeutic drug monitoring of the immunosuppressive agent recommended and consultation with a specialist may be needed200

Indinavir

Decreased indinavir concentrations and AUC; no clinically important change in nevirapine pharmacokinetics1 234

No in vitro evidence of antagonistic antiretroviral effects1 234

Appropriate dosages for concomitant use with respect to safety and efficacy not established1 234

Lamivudine

No in vitro evidence of antagonistic antiretroviral effects1 234

Ledipasvir and sofosbuvir

Fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir): Clinically important interactions not expected200

Ledipasvir/sofosbuvir: Dosage adjustments not needed200

Leuprolide

Altered leuprolide concentrations not expected200

Lopinavir and ritonavir

Fixed combination of lopinavir and ritonavir (lopinavir/ritonavir): Decreased lopinavir concentrations and AUC1 207 234

Lopinavir/ritonavir (once-daily regimen): Not recommended with nevirapine207

Lopinavir/ritonavir (twice-daily regimen): Increased lopinavir/ritonavir dosage recommended;1 207 234 dosage depends on lopinavir/ritonavir preparation used (tablets, oral solution) and clinical characteristics of the patient207

Macrolides

Clarithromycin: Decreased clarithromycin concentration and increased 14-hydroxyclarithromycin concentration;1 200 234 possible increased nevirapine AUC200

Monitor for efficacy of the macrolide or use an alternative (e.g., azithromycin) for treatment or prophylaxis of MAC1 200 234

Maraviroc

No effect on maraviroc AUC200

No in vitro evidence of antagonistic antiretroviral effects224

Recommended maraviroc dosage is 300 mg twice daily when used with nevirapine, provided regimen does not include a PI or other potent CYP3A inhibitor;200 224 recommended maraviroc dosage is 150 mg twice daily if used with nevirapine in a regimen that includes a PI (except ritonavir-boosted tipranavir)200 224

Methadone

Decreased methadone concentrations;1 234 no change in nevirapine concentrations200

Opiate withdrawal reported200

Consider need to increase methadone dosage1 200 234

Nefazodone

Decreased nefazodone concentrations expected;200 possible increased nevirapine concentrations200

Monitor for nefazodone therapeutic effects and titrate antidepressant dosage as needed;200 also monitor for nevirapine-associated adverse effects200

Nelfinavir

No effect on nelfinavir peak concentrations or AUC;1 234 decreased nelfinavir trough concentrations and substantially decreased concentrations and AUC of major nelfinavir metabolite (M8).1 234

No in vitro evidence of antagonistic antiretroviral effects1 234

Appropriate dosages for concomitant use with respect to safety and efficacy not established1 234

Quinupristin and dalfopristin

Possible increased nevirapine concentrations77

Raltegravir

No in vitro evidence of antagonistic antiretroviral effects225

Dosage adjustments not necessary200

Rilpivirine

Possible altered rilpivirine concentrations1 234

Do not use concomitantly1 234

Ritonavir

No clinically important pharmacokinetic interactions1 234

St. John’s wort (Hypericum perforatum)

Decreased nevirapine concentrations; possible loss of virologic response and increased risk of nevirapine resistance1 78 79 200 234

Concomitant use contraindicated200

Saquinavir

Ritonavir-boosted saquinavir: Concomitant use not evaluated1 234

No in vitro evidence of antagonistic antiretroviral effects1 234

Ritonavir-boosted saquinavir: Appropriate dosages for concomitant use with respect to safety and efficacy not established1 234

Sildenafil

Possible decreased sildenafil concentrations200

May need to increase sildenafil dosage based on clinical effects200

Simeprevir

Decreased simeprevir concentrations expected200

Do not use concomitantly200

Sofosbuvir and velpatasvir

Fixed combination of sofosbuvir and velpatasvir (sofosbuvir/velpatasvir): Decreased velpatasvir concentrations expected200

Sofosbuvir/velpatasvir: Do not use concomitantly200

Sofosbuvir, velpatasvir, and voxilaprevir

Fixed combination of sofosbuvir, velpatasvir, and voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir): Decreased velpatasvir and voxilaprevir concentrations expected200

Sofosbuvir/velpatasvir/voxilaprevir: Do not use concomitantly200

Spironolactone

Altered spironolactone concentrations not expected200

SSRIs

Citalopram, escitalopram: Possible decreased SSRI concentrations200

Fluoxetine, fluvoxamine, paroxetine: Altered SSRI concentrations not expected200

Citalopram, escitalopram: Titrate SSRI dosage based on clinical response200

Fluoxetine, fluvoxamine, paroxetine: Dosage adjustments not needed200

Stavudine

No clinically important effect on stavudine concentrations or AUC1 234

No in vitro evidence of antagonistic antiretroviral effects1 234

Tadalafil

Possible decreased tadalafil concentrations200

May need to increase tadalafil dosage based on clinical effects200

Tenofovir

No in vitro evidence of antagonistic antiretroviral effects1 234

Testosterone

Possible decreased testosterone concentrations200

Monitor for testosterone effects and adjust testosterone dosage if needed200

Tipranavir

Ritonavir-boosted tipranavir: No clinically important effect on nevirapine concentrations;1 200 234 altered tipranavir concentrations not expected200

No in vitro evidence of antagonistic antiretroviral effects1 234

Ritonavir-boosted tipranavir: Experts state dosage adjustments not needed200

Trazodone

Possible decreased trazodone concentrations200

Monitor for trazodone therapeutic effects and titrate trazodone dosage as needed200

Vardenafil

Possible decreased vardenafil concentrations200

May need to increase vardenafil dosage based on clinical effects200

Zidovudine

Decreased zidovudine concentrations1 234

No in vitro evidence of antagonistic antiretroviral effects1 234

Nevirapine Pharmacokinetics

Absorption

Bioavailability

Immediate-release nevirapine: Well absorbed from GI tract; absolute bioavailability is 91–93%.1 75 Peak plasma concentrations attained within 4 hours.1

Extended-release tablets: Peak plasma concentrations attained at a median of approximately 24 hours after dose.234

Commercially available immediate-release tablets and oral suspension are bioequivalent at dose ≤200 mg.1

Bioavailability of 400 mg of nevirapine as extended-release tablets relative to 400 mg as immediate-release tablets is approximately 75%.234

Food

Food does not appear to affect absorption of immediate-release tablets.1

Difference in bioavailability of nevirapine extended-release tablets under fasted or fed conditions not considered clinically important.234

Special Populations

Immediate-release nevirapine in children: Steady-state trough concentrations similar to concentrations in adults receiving recommended dosage.1

Extended-release tablets in children 6 to <18 years: Overall mean systemic nevirapine exposure after switch from immediate-release to extended-release nevirapine similar to that reported with immediate-release.234

Immediate-release nevirapine in pregnant women: Pharmacokinetics generally similar to that reported in nonpregnant adults;202 dosage adjustments not recommended during pregnancy.202

Immediate-release tablets in patients with mild, moderate, or severe renal impairment: Pharmacokinetics not altered.1 AUC decreased in individuals requiring dialysis.1 Accumulation of nevirapine metabolites noted in individuals requiring dialysis.1

Immediate-release tablets in patients with mild to moderate hepatic impairment: Pharmacokinetics not altered in most patients; trough concentrations twofold higher in 15% of patients with hepatic fibrosis.1 Increased nevirapine AUC noted in 1 patient with moderate hepatic impairment (Child-Pugh class B) and ascites.1

Extended-release tablets: Not studied in pregnant women202 or in patients with hepatic or renal impairment.234

Distribution

Extent

Distributed into CSF; concentrations in CSF are 45% of concurrent plasma concentrations.1

Crosses placenta;1 65 distributed into human milk58 65 1 and semen.88

Plasma Protein Binding

60%.1

Elimination

Metabolism

Metabolized by CYP3A and CYP2B6.1

Elimination Route

Excreted in urine (81%) mainly as glucuronide conjugates of hydroxylase metabolites and in feces (10%).1

Half-life

45 hours after a single dose and 25–30 hours after multiple doses.1

Special Populations

Clearance greater in children than adults.1

Stability

Storage

Oral

Tablets

Conventional (immediate-release): 25°C (may be exposed to 15–30°C).1

Extended-release: 25°C (may be exposed to 15–30°C).234

Suspension

25°C (may be exposed to 15–30°C).1

Actions and Spectrum

  • Pharmacologically related to other NNRTIs (e.g., delavirdine, efavirenz, etravirine, rilpivirine); differs structurally from these drugs; also differs pharmacologically and structurally from other currently available antiretrovirals.1 21

  • Active against HIV-1; inactive against HIV-2.1 3 22 71

  • Nevirapine inhibits replication of HIV-1 by interfering with viral RNA- and DNA-directed polymerase activities of reverse transcriptase.1 3

  • HIV-1 with reduced susceptibility to nevirapine have been selected in vitro and have emerged during therapy with the drug.1 3 5 21 22

  • Strains of HIV-1 resistant to nevirapine may be cross-resistant to some other NNRTIs.1 28 42

  • Cross-resistance between nevirapine and NRTIs unlikely since the drugs bind at difference sites on reverse transcriptase and have difference mechanisms of action.1 Cross-resistance between nevirapine and HIV protease inhibitors (PIs) unlikely since the drugs have different target enzymes and mechanisms of action.1

Advice to Patients

  • Critical nature of compliance with HIV therapy and importance of remaining under the care of a clinician.1 234 Importance of taking as prescribed; do not alter or discontinue antiretroviral regimen without consulting clinician.1 234

  • Importance of using in conjunction with other antiretrovirals— not for monotherapy.1 234

  • Antiretroviral therapy is not a cure for HIV infection; opportunistic infections and other complications associated with HIV disease may still occur.1 234

  • Advise patients that effective antiretroviral regimens can decrease HIV concentrations in blood and genital secretions and strict adherence to such regimens in conjunction with risk-reduction measures may decrease, but cannot absolutely eliminate, the risk of secondary transmission of HIV to others.200 Importance of continuing to practice safer sex (e.g., using latex or polyurethane condoms to minimize sexual contact with body fluids), never sharing personal items that can have blood or body fluids on them (e.g., toothbrushes, razor blades), and never reusing or sharing needles.1 234 200

  • Importance of reading patient information provided by the manufacturer.1 234

  • If a dose is missed, the next dose should be taken as soon as possible.1 234 If a dose is skipped, do not take a double dose to make up for the missed dose.1 234

  • Possibility of severe liver disease or skin reactions (potentially fatal).1 234 Importance of discontinuing nevirapine and seeking immediate medical attention if signs or symptoms of liver disease (fatigue, malaise, anorexia, nausea, jaundice, acholic stools, liver tenderness, hepatomegaly) or severe skin or hypersensitivity reactions (rash accompanied by fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial edema, hepatitis) occur.1 234

  • Need for intensive clinical and laboratory monitoring, including liver enzymes, during first 18 weeks of therapy (especially first 6 weeks) and importance of frequent monitoring throughout nevirapine treatment.1 234

  • Risk of rash, especially during first 6 weeks of therapy.1 234 If rash occurs during first 2 weeks of therapy, do not increase nevirapine dosage and do not switch to extended-release tablets until rash resolves.1 234

  • Redistribution/accumulation of body fat may occur, with as yet unknown long-term health effects.1 234

  • Advise patients to immediately contact a clinician if they have any signs or symptoms of infection since inflammation from previous infections may occur soon after antiretroviral therapy is initiated.1 234

  • To avoid overdosage, do not use immediate-release nevirapine (tablets or oral suspension) and extended-release nevirapine (tablets) concomitantly.1 234

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal products.1 234

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 234 Advise HIV-infected women not to breast-feed.1 234

  • Importance of advising patients of other important precautionary information.1 234 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Nevirapine

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets

200 mg*

Nevirapine Tablets

Viramune (scored)

Boehringer Ingelheim

Tablets, extended-release

100 mg*

Nevirapine Extended-release Tablets

Viramune XR

Boehringer Ingelheim

400 mg*

Nevirapine Extended-release Tablets

Viramune XR

Boehringer Ingelheim

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Nevirapine Hemihydrate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Suspension

50 mg (of nevirapine) per 5 mL*

Nevirapine Oral Suspension

Viramune

Boehringer Ingelheim

AHFS DI Essentials™. © Copyright 2018, Selected Revisions August 13, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Boehringer Ingelheim. Viramune (nevirapine) tablets and oral suspension prescribing information. Ridgefield, CT; 2017 Mar.

2. Havlir D, Cheeseman SH, McLaughlin M et al. High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis. 1995; 171:537-45. http://www.ncbi.nlm.nih.gov/pubmed/7533197?dopt=AbstractPlus

3. Richman D, Rosenthal AS, Skoog M et al. BI-RG-587 is active against zidovudine- resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother. 1991; 35:305-8. http://www.ncbi.nlm.nih.gov/pubmed/1708976?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=244996&blobtype=pdf

4. Cheeseman SH, Havlir D, McLaughlin MM et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 8:141-51. http://www.ncbi.nlm.nih.gov/pubmed/7530585?dopt=AbstractPlus

5. Kohlstaedt LA, Wang J, Friedman JM et al. Crystal structure at 3.5 resolution of HIV- 1 reverse transcriptase complexed with an inhibitor. Science. 1992; 256:1783-90. http://www.ncbi.nlm.nih.gov/pubmed/1377403?dopt=AbstractPlus

6. D’Aquila RT, Hughes MD, Johnson VA et al. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intern Med. 1996; 124:1019-30. http://www.ncbi.nlm.nih.gov/pubmed/8633815?dopt=AbstractPlus

9. Merrill DP, Moonis M, Chou TC et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996; 173:355-64. http://www.ncbi.nlm.nih.gov/pubmed/8568296?dopt=AbstractPlus

13. Montaner JSG, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA. 1998; 279:930-7. http://www.ncbi.nlm.nih.gov/pubmed/9544767?dopt=AbstractPlus

16. Reviewers’ comments (personal observations) on saquinavir.

20. Luzuriaga K, Bryson Y, Krogstad P et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus infection. N Engl J Med. 1997; 336:1343-9. http://www.ncbi.nlm.nih.gov/pubmed/9134874?dopt=AbstractPlus

21. Spence RA, Kati WM, Anderson KS et al. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 1995; 267:988-93. http://www.ncbi.nlm.nih.gov/pubmed/7532321?dopt=AbstractPlus

22. Merluzzi VJ, Hargrave KD, Labadia M et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 1990; 250:1411-13. http://www.ncbi.nlm.nih.gov/pubmed/1701568?dopt=AbstractPlus

24. Anon. Boehringer Ingleheim Viramune for combination use will be on the market by end of July; interaction studies with protease inhibitors part of Phase IV. F-D-C Rep. 1996; July 1: T&G 7-8.

27. Zhu QY, Scarborough A, Polsky B et al. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Res Hum Retroviruses. 1996; 12:507-17. http://www.ncbi.nlm.nih.gov/pubmed/8679306?dopt=AbstractPlus

28. Byrnes VW, Sardana VV, Schleif WA et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob Agents Chemother. 1993; 27:1576-9.

42. Moyle GJ. Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunol Infect Dis. 1995; 5:170-82.

43. Imrie A, Beveridge A, Genn W et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine. J Infect Dis. 1997; 175:1502-6. http://www.ncbi.nlm.nih.gov/pubmed/9180194?dopt=AbstractPlus

46. Meyers MW. Dear doctor letter regarding ongoing pharmacokinetic interaction trials with nevirapine and the protease inhibitors saquinavir, indinavir and ritonavir. Ridgefield, CT: Boehringer Ingelheim; 1996 Sept 23.

47. Meyers MW. Dear investigator letter regarding VIRAMUNE in combination with protease inhibitors. Ridgefield, CT: Boehringer Ingelheim; 1996 Nov 20.

48. Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT: Personal communication.

49. Roxane Laboratories, Inc. Management of rash associated with Viramune (nevirapine). Ridgefield, CT; 1996 Sept.

58. Musoke P, Guay LA, Bagenda D et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999; 13:479-86. http://www.ncbi.nlm.nih.gov/pubmed/10197376?dopt=AbstractPlus

59. Guay LA, Musoke p, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999; 354:795-802. http://www.ncbi.nlm.nih.gov/pubmed/10485720?dopt=AbstractPlus

60. Marseille E, Kahn JG, Mmiro F et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999; 354:803-9. http://www.ncbi.nlm.nih.gov/pubmed/10485721?dopt=AbstractPlus

61. National Institute of Allergy and Infectious Diseases. HIVNET 012: questions and answers. News release. 1999 July 8.

65. Mirochnick M, Fenton T, Gagnier P et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis. 1998; 178:368-74. http://www.ncbi.nlm.nih.gov/pubmed/9697716?dopt=AbstractPlus

66. Warren KJ, Boxwell DE, Kim NY et al. Nevirapine-associated Stevens-Johnson syndrome. Lancet. 1998; 351:567. http://www.ncbi.nlm.nih.gov/pubmed/9492778?dopt=AbstractPlus

67. Barner A, Myers M. Nevirapine and rashes. Lancet. 1998; 351:1133. http://www.ncbi.nlm.nih.gov/pubmed/9660609?dopt=AbstractPlus

69. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS. 1999; 13:957-62. http://www.ncbi.nlm.nih.gov/pubmed/10371177?dopt=AbstractPlus

70. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy. 1999; 19:471-2. http://www.ncbi.nlm.nih.gov/pubmed/10212021?dopt=AbstractPlus

71. Witvrouw M, Pannecouque C, Van Laethem K et al. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999; 13:1477-83. http://www.ncbi.nlm.nih.gov/pubmed/10465070?dopt=AbstractPlus

72. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep. 1998; 47(No. RR-20).

73. Centers for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep. 2000; 49:185-9. http://www.ncbi.nlm.nih.gov/pubmed/11795500?dopt=AbstractPlus

74. Riska P, Lamson M, MacGregor T et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999; 27:895-901. http://www.ncbi.nlm.nih.gov/pubmed/10421616?dopt=AbstractPlus

75. Lamson MJ, Sabo JP, MacGregor TR et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos. 1999; 20:285-91. http://www.ncbi.nlm.nih.gov/pubmed/10701699?dopt=AbstractPlus

76. Taylor S, Little J, Halifax K et al. Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory, peritoneal dialysis. J Antimicrob Chemother. 2000; 45:716-7. http://www.ncbi.nlm.nih.gov/pubmed/10797104?dopt=AbstractPlus

77. Rhone-Poulenc Rorer Pharmaceuticals Inc. Synercid I.V. (quinupristin and dalfopristin) prescribing information. Collegeville, PA; 1999 Jul.

78. Lumpkin MM, Alpert A. Risk of drug interactions with St John’s wort and indinavir and other drugs. FDA Public Health Advisory. 2000 Feb 10. From FDA website. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm052238.htm

79. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St John’s wort. Lancet. 2000; 355:547-8. http://www.ncbi.nlm.nih.gov/pubmed/10683007?dopt=AbstractPlus

80. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999; 66:338-45. http://www.ncbi.nlm.nih.gov/pubmed/10546917?dopt=AbstractPlus

81. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John’s wort. Lancet. 2000; 355:548-9. http://www.ncbi.nlm.nih.gov/pubmed/10683008?dopt=AbstractPlus

82. Taylor GP, Lyall EGH, Back D et al. Pharmacological implications of lengthened in-utero exposure to nevirapine. Lancet. 2000; 355:2134-5. http://www.ncbi.nlm.nih.gov/pubmed/10902630?dopt=AbstractPlus

84. American Thoracic Society (ATS) and Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infections. Am J Respir Crit Care Med. 2000; 161:S221-47.

85. Krogstad P, Lee S, Johnson G et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002; 34:991-1001. http://www.ncbi.nlm.nih.gov/pubmed/11880966?dopt=AbstractPlus

86. Roxane Laboratories, Inc. Important drug warning re. severe, life-threatening and fatal cases of hepatotoxicity with Viramune. Ridgefield, CT; 2000 Nov.

87. Anon. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures: worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001; 49:1153-6. http://www.ncbi.nlm.nih.gov/pubmed/11198946?dopt=AbstractPlus

88. Taylor S, van Heeswijk RP, Hoetelmans RM et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS. 2000; 14:1979-84. http://www.ncbi.nlm.nih.gov/pubmed/10997403?dopt=AbstractPlus

91. Yogev R, Lee S, Wiznia A et al. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2002; 21:119-25. http://www.ncbi.nlm.nih.gov/pubmed/11840078?dopt=AbstractPlus

92. Coovadia HM, Brown ER, Fowler MG et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379:221-8. http://www.ncbi.nlm.nih.gov/pubmed/22196945?dopt=AbstractPlus

96. US Food and Drug Administration. FDA public health advisory for neveripine (Viramune). 2005 Jan 19. From FDA web site. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051674.htm

101. Lipman M, Breen R. Immune reconstitution inflammatory syndrome in HIV. Curr Opin Infect Dis. 2006; 19:20-5. http://www.ncbi.nlm.nih.gov/pubmed/16374213?dopt=AbstractPlus

178. Bristol-Myers Squibb. Daklinza (daclatasvir) tablets prescribing information. Princeton, NJ. 2017 Feb.

198. Centers for Disease Control and Prevention. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV – United States, 2016. From HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

199. Kuhar DT, Henderson DK, Struble KA et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013; 34:875-92. http://www.ncbi.nlm.nih.gov/pubmed/23917901?dopt=AbstractPlus

200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV (October 17, 2017). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

201. Panel on Antiretroviral Therapy and Medical Management of HIV-infected Children, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in pediatric HIV infection (April 27, 2017). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

202. Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission, US Department of Health and Human Services (HHS). Recommendations for use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States (November 14, 2017). Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

203. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules and oral powder prescribing information. Princeton, NJ; 2016 Sep.

204. Janssen Therapeutics. Prezista (darunavir) oral suspension and film-coated tablets prescribing information. Titusville, NJ; 2016 Sep.

205. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2016 Sep.

207. AbbVie Inc. Kaletra (lopinavir/ritonavir) film-coated tablets and oral solution prescribing information. North Chicago, IL; 2016 Sep.

224. ViiV Healthcare. Selzentry (maraviroc) tablets and oral solution prescribing information. Research Triangle Park, NC; 2016 Nov.

225. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets, chewable tablets, and for oral suspension and Isentress HD (raltegravir) film-coated tablets prescribing information. Whitehouse Station, NJ; 2017 Nov.

234. Boehringer Ingelheim. Viramune XR (nevirapine) extended-release tablets prescribing information. Ridgefield, CT; 2017 Mar.

236. ViiV Healthcare. Tivicay (dolutegravir) tablets prescribing information. Research Triangle Park, NC; 2017 Mar.

238. Bristol-Myers Squibb. Evotaz (atazanavir/cobicistat) tablets prescribing information. Princeton, NJ; 2016 Jul.

Hide